dynorphins has been researched along with Cardiovascular-Diseases* in 3 studies
3 review(s) available for dynorphins and Cardiovascular-Diseases
Article | Year |
---|---|
Dynorphins in Development and Disease: Implications for Cardiovascular Disease.
It is well-established that cardiovascular disease continues to represent a growing health problem and significant effort has been made to elucidate the underlying mechanisms. In this review, we report on past and recent high impact publications in the field of intracrine network signaling, focusing specifically on opioids and their interrelation with key modulators of the cardiovascular system and the onset of related disease. We present an overview of studies outlining the scope of cardiovascular and cerebrovascular processes that are affected by opioids, including heart function, ischemia, reperfusion, and blood flow. Specific emphasis is placed on the importance of dynorphin molecules in cerebrovascular and cardiovascular regulation. Evidence suggests that excessive or insufficient dynorphin could make an important contribution to cardiovascular physiology, yet numerous paradoxical observations frequently impede a clear understanding of the role of dynorphin. Thus, we argue that dynorphin-mediated signaling events for which an immediate regulatory effect is disputed should not be dismissed as unimportant, as they may play a role in cross-talk with other signaling networks. Finally, we consider the most recent evidence on the role of dynorphin during cardiovascular-related inflammation and on the potential value of endogenous and exogenous inhibitors of kappa-opioid receptor, a major dynorphin A receptor, to limit or prevent cardiovascular disease and its related sequelae. Topics: Amino Acid Sequence; Animals; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Dynorphins; Fetal Development; Humans | 2020 |
Opioid and nonopioid cardiovascular effects of dynorphins.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Dynorphins; Humans | 1997 |
Opioid biology: the next set of questions.
A range of biologically different opioid peptides are synthesised as components of three distinct precursors, pro-opiomelanocortin, proenkephalin, and prodynorphin. They interact with a number of receptors which have so far been characterised as mu, delta, kappa, sigma, and epsilon. It is unclear which ligands bind to which receptors under physiological circumstances, but preferential in vitro interactions include enkephalins with delta receptors, dynorphin with kappa receptors, and beta-endorphin with epsilon receptors. Post-translational processing determines which of several opioid products are produced from each precursor, but the identity of the enzymes involved and regulation of processing is unknown. Opioid involvement in the neuroendocrine and cardiovascular systems is reviewed. Naloxone-sensitive opioid mechanisms are implicated in the control of gonadotrophin and adrenocorticotropic hormone secretion and in the hypotension of various types of shock. The investigation of possible dynorphin involvement in neurohypophysial function is taking place because vasopressin and dynorphin A (1-8) have been shown to coexist in the neurosecretory vesicles of magnocellular neurons. Topics: Cardiovascular Diseases; Dynorphins; Endocrine System Diseases; Endorphins; Enkephalins; Female; Humans; Male; Nervous System Diseases; Protein Processing, Post-Translational; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa | 1985 |